isomethyleugenol has been researched along with Barrett Epithelium in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (63.64) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Banazadeh, A; Mechref, Y; Peng, W; Zhong, J | 1 |
| Desantos-Garcia, JL; Hu, Y; Mechref, Y | 1 |
| Belshaw, N; Hindmarsh, A; Johnson, IT; Mehta, S; Rhodes, M | 1 |
| Canto, MI; Forastiere, AA; Gordon, G; Hawk, E; Heath, EI; Piantadosi, S; Unalp, A; Wu, TT | 1 |
| Ahlquist, DA; Burgart, LJ; Harrington, JJ; Klatt, KK; Molina, JR; Osborn, NK; Zou, H | 1 |
| Ell, C; Hengge, UR; Schmidt, WE; Stolte, M; Tannapfel, A; Tischoff, I; Vieth, M; Weber, A | 1 |
| Abraham, JM; Canto, M; Cheng, Y; David, S; Feng, Z; Fredericksen, MB; Greenwald, BD; Hamilton, JP; Ito, T; Jin, Z; Kan, T; Meltzer, SJ; Mori, Y; Olaru, A; Paun, B; Romero, Y; Sato, F; Schulmann, K; Wang, J; Wang, KK; Wu, TT; Yang, J; Yfantis, HG | 1 |
| Fitzgerald, RC; Gjerset, RA; Huang, Y; Peters, CJ | 1 |
| Anderson, MA; Buttar, NS; Krishnadath, KK; Liu, W; Lutzke, LS; Sebo, TJ; Taniguchi, K; Wang, KK | 1 |
| Abraham, JM; Beer, DG; Brabender, J; Danenberg, KD; Danenberg, PV; Demeester, TR; Eads, C; Fleisher, AS; Greenwald, BD; Groshen, S; Harpole, D; Huss, HT; Ilson, DH; Kawakami, K; Kelsen, DP; Krasna, MJ; Laird, PW; Lord, RV; Meltzer, SJ; Moore, MB; Sidransky, D; Yin, J | 1 |
| Meltzer, SJ; Weinstein, WM; Zhou, D | 1 |
1 review(s) available for isomethyleugenol and Barrett Epithelium
| Article | Year |
|---|---|
Chemoprevention for Barrett's esophagus trial. Design and outcome measures.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Barrett Esophagus; Cyclooxygenase Inhibitors; Genes, Tumor Suppressor; Humans; Methylation; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome | 2003 |
1 trial(s) available for isomethyleugenol and Barrett Epithelium
| Article | Year |
|---|---|
Chemoprevention for Barrett's esophagus trial. Design and outcome measures.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Barrett Esophagus; Cyclooxygenase Inhibitors; Genes, Tumor Suppressor; Humans; Methylation; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome | 2003 |
10 other study(ies) available for isomethyleugenol and Barrett Epithelium
| Article | Year |
|---|---|
A carbon nanoparticles-based solid-phase purification method facilitating sensitive MALDI-MS analysis of permethylated N-glycans.
Topics: Barrett Esophagus; Carbon; Esophageal Neoplasms; Glycomics; Humans; Methylation; Nanoparticles; Polysaccharides; Solid Phase Extraction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2018 |
Comparative glycomic profiling of isotopically permethylated N-glycans by liquid chromatography/electrospray ionization mass spectrometry.
Topics: Barrett Esophagus; Carbohydrate Conformation; Case-Control Studies; Chromatography, Liquid; Esophageal Neoplasms; Glycomics; Glycoproteins; Humans; Methylation; Models, Chemical; Polysaccharides; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2013 |
Can the rat be used as a valid model of human esophageal adenocarcinoma?
Topics: Adenocarcinoma; Animals; Barrett Esophagus; CpG Islands; Disease Models, Animal; Esophageal Neoplasms; Esophagus; Gastroesophageal Reflux; Humans; Methylation; Rats | 2012 |
Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Barrett Esophagus; Biomarkers, Tumor; Esophageal Neoplasms; Female; Humans; Male; Methylation; Middle Aged; Trans-Activators | 2005 |
Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma.
Topics: Adenocarcinoma; Barrett Esophagus; Carcinoma in Situ; Carcinoma, Squamous Cell; Cell Line, Tumor; CpG Islands; DNA, Neoplasm; Esophageal Neoplasms; Humans; Methylation; Neoplasm Proteins; Promoter Regions, Genetic; Suppressor of Cytokine Signaling 1 Protein; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Transcription, Genetic | 2007 |
Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features.
Topics: Barrett Esophagus; Cell Differentiation; Disease Progression; Disease-Free Survival; Endoscopy; Epigenesis, Genetic; Esophageal Neoplasms; Humans; Methylation; Precancerous Conditions; Reproducibility of Results; Risk; Risk Assessment; ROC Curve; Treatment Outcome | 2008 |
Progressive silencing of p14ARF in oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Barrett Esophagus; Base Sequence; Cell Line; Decitabine; Disease Progression; Epithelial Cells; Esophageal Neoplasms; Female; Gene Silencing; Histones; Humans; Male; Methylation; Middle Aged; Molecular Sequence Data; Survival Rate; Tumor Suppressor Protein p14ARF | 2009 |
Persistent genetic abnormalities in Barrett's esophagus after photodynamic therapy.
Topics: Aged; Aneuploidy; Barrett Esophagus; Cyclin-Dependent Kinase Inhibitor p16; Esophagus; Follow-Up Studies; Humans; Male; Methylation; Middle Aged; Photochemotherapy; Point Mutation; Promoter Regions, Genetic; Tumor Suppressor Protein p53 | 2000 |
Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adenomatous Polyposis Coli; Barrett Esophagus; Biomarkers, Tumor; Carcinoma, Squamous Cell; Chi-Square Distribution; Chromosomes, Human, Pair 5; DNA, Neoplasm; Esophageal Neoplasms; Gastric Mucosa; Humans; Loss of Heterozygosity; Methylation; Polymerase Chain Reaction; Precancerous Conditions; Prognosis; Promoter Regions, Genetic; Survival Analysis | 2000 |
Tissue-specific expression of c-Ha-ras in premalignant gastrointestinal mucosae.
Topics: Adenomatous Polyposis Coli; Barrett Esophagus; Colitis, Ulcerative; Colon; Gene Amplification; Humans; Intestinal Mucosa; Methylation; Oncogene Protein p21(ras); Oncogene Proteins; Phosphoproteins; Precancerous Conditions; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-myc; Proto-Oncogenes; Tumor Suppressor Protein p53 | 1989 |